Horeweg, Nanda http://orcid.org/0000-0002-8581-4753
Workel, Hagma H.
Loiero, Dominik http://orcid.org/0000-0002-0452-0068
Church, David N.
Vermij, Lisa
Léon-Castillo, Alicia
Krog, Ricki T. http://orcid.org/0000-0002-0201-7207
de Boer, Stephanie M.
Nout, Remi A.
Powell, Melanie E.
Mileshkin, Linda R.
MacKay, Helen
Leary, Alexandra
Singh, Naveena
Jürgenliemk-Schulz, Ina M.
Smit, Vincent T. H. B. M.
Creutzberg, Carien L. http://orcid.org/0000-0002-7008-4321
Koelzer, Viktor H. http://orcid.org/0000-0001-9206-4885
Nijman, Hans W.
Bosse, Tjalling
de Bruyn, Marco http://orcid.org/0000-0001-9819-9131
Horeweg, Nanda http://orcid.org/0000-0002-8581-4753
Church, David N.
de Boer, Stephanie M.
Nout, Remi A.
Powell, Melanie E.
Mileshkin, Linda R.
MacKay, Helen
Leary, Alexandra
Singh, Naveena
Creutzberg, Carien L.
Nijman, Hans W.
Bosse, Tjalling
de Bruyn, Marco http://orcid.org/0000-0001-9819-9131
,
Funding for this research was provided by:
KWF Kankerbestrijding (KWF-2021-13400, KWF-2021-13404, 2018-1-11629, 2018-1-11629, 2018-1-11629, 2018-1-11629, RUG 2015-7235, 8232-21648)
Wellcome Trust (203141/Z/16/Z)
Cancer Research UK (C26642/A27963)
Promedica Stiftung (F-87701-41-01)
Article History
Received: 2 July 2021
Accepted: 23 February 2022
First Online: 16 March 2022
Competing interests
: Dr. Horeweg reports outside of the submitted work to have received research grants from the Dutch Cancer Society (KWF-2021-13400, KWF-2021-13404). Dr. Church is funded by a Cancer Research UK Advanced Clinician Scientist Fellowship (C26642/A27963) and reports to be part of the advisory board for MSD. Prof. Nout, Dr. Bosse and Prof. Creutzberg report to have received a grant from the Dutch Cancer Society for the PORTEC-3 trial (KWF 2018-1-11629). Prof. Koelzer reports grants from Promedica Foundation (F-87701-41-01) during the conduct of the study and having served as an invited speaker on behalf of Indica Labs. Dr. de Bruyn reports, outside the submitted work, having received grants from the Dutch Cancer Society (KWF), grants from the European Research Council (ERC), grants from Health Holland, grants from DCPrime, non-financial support from BioNTech, non-financial support from Surflay, non-financial support from MSD, grants and non-financial support from Vicinivax. In addition, dr. de Bruyn has grants and non-financial support from Aduro Biotech, in part relating to a patent for Antibodies targeting CD103 (de Bruyn et al. No. 62/704,258). The remaining authors declare no competing interests.